nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—hematologic cancer—muscle cancer	0.887	1	CtDrD
Anagrelide—CYP1A2—Dacarbazine—muscle cancer	0.0316	0.672	CbGbCtD
Anagrelide—CYP1A2—Etoposide—muscle cancer	0.0154	0.329	CbGbCtD
Anagrelide—Anaemia—Etoposide—muscle cancer	0.000164	0.00248	CcSEcCtD
Anagrelide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000164	0.00247	CcSEcCtD
Anagrelide—Liver function test abnormal—Methotrexate—muscle cancer	0.000163	0.00246	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000163	0.00246	CcSEcCtD
Anagrelide—Insomnia—Vincristine—muscle cancer	0.000162	0.00244	CcSEcCtD
Anagrelide—Renal impairment—Doxorubicin—muscle cancer	0.000161	0.00243	CcSEcCtD
Anagrelide—Paraesthesia—Vincristine—muscle cancer	0.00016	0.00243	CcSEcCtD
Anagrelide—Malaise—Etoposide—muscle cancer	0.00016	0.00242	CcSEcCtD
Anagrelide—Abdominal pain—Dactinomycin—muscle cancer	0.000158	0.00239	CcSEcCtD
Anagrelide—Body temperature increased—Dactinomycin—muscle cancer	0.000158	0.00239	CcSEcCtD
Anagrelide—Cardiac failure—Doxorubicin—muscle cancer	0.000157	0.00237	CcSEcCtD
Anagrelide—Loss of consciousness—Etoposide—muscle cancer	0.000156	0.00236	CcSEcCtD
Anagrelide—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000156	0.00236	CcSEcCtD
Anagrelide—Decreased appetite—Vincristine—muscle cancer	0.000155	0.00235	CcSEcCtD
Anagrelide—Cough—Etoposide—muscle cancer	0.000155	0.00234	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Vincristine—muscle cancer	0.000154	0.00233	CcSEcCtD
Anagrelide—Fatigue—Vincristine—muscle cancer	0.000154	0.00233	CcSEcCtD
Anagrelide—Convulsion—Etoposide—muscle cancer	0.000154	0.00232	CcSEcCtD
Anagrelide—Hypertension—Etoposide—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Pain—Vincristine—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Constipation—Vincristine—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Osteoarthritis—Doxorubicin—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Diplopia—Doxorubicin—muscle cancer	0.000153	0.00231	CcSEcCtD
Anagrelide—Asthma—Methotrexate—muscle cancer	0.000152	0.0023	CcSEcCtD
Anagrelide—Chest pain—Etoposide—muscle cancer	0.000151	0.00228	CcSEcCtD
Anagrelide—Migraine—Doxorubicin—muscle cancer	0.00015	0.00227	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00015	0.00227	CcSEcCtD
Anagrelide—Pancreatitis—Methotrexate—muscle cancer	0.000149	0.00226	CcSEcCtD
Anagrelide—Discomfort—Etoposide—muscle cancer	0.000149	0.00226	CcSEcCtD
Anagrelide—Abdominal discomfort—Methotrexate—muscle cancer	0.000146	0.00221	CcSEcCtD
Anagrelide—Gastrointestinal pain—Vincristine—muscle cancer	0.000146	0.00221	CcSEcCtD
Anagrelide—Confusional state—Etoposide—muscle cancer	0.000146	0.00221	CcSEcCtD
Anagrelide—Pancytopenia—Methotrexate—muscle cancer	0.000145	0.00219	CcSEcCtD
Anagrelide—Infection—Etoposide—muscle cancer	0.000144	0.00217	CcSEcCtD
Anagrelide—Asthenia—Dactinomycin—muscle cancer	0.000143	0.00217	CcSEcCtD
Anagrelide—Blood creatinine increased—Doxorubicin—muscle cancer	0.000143	0.00216	CcSEcCtD
Anagrelide—Dysuria—Methotrexate—muscle cancer	0.000143	0.00216	CcSEcCtD
Anagrelide—Dehydration—Doxorubicin—muscle cancer	0.000142	0.00215	CcSEcCtD
Anagrelide—Thrombocytopenia—Etoposide—muscle cancer	0.000142	0.00214	CcSEcCtD
Anagrelide—Tachycardia—Etoposide—muscle cancer	0.000141	0.00214	CcSEcCtD
Anagrelide—Body temperature increased—Vincristine—muscle cancer	0.000141	0.00214	CcSEcCtD
Anagrelide—Abdominal pain—Vincristine—muscle cancer	0.000141	0.00214	CcSEcCtD
Anagrelide—Liver function test abnormal—Doxorubicin—muscle cancer	0.000141	0.00213	CcSEcCtD
Anagrelide—Skin disorder—Etoposide—muscle cancer	0.000141	0.00213	CcSEcCtD
Anagrelide—Erectile dysfunction—Methotrexate—muscle cancer	0.00014	0.00212	CcSEcCtD
Anagrelide—Dry skin—Doxorubicin—muscle cancer	0.00014	0.00212	CcSEcCtD
Anagrelide—Hyperhidrosis—Etoposide—muscle cancer	0.00014	0.00212	CcSEcCtD
Anagrelide—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00014	0.00211	CcSEcCtD
Anagrelide—Photosensitivity reaction—Methotrexate—muscle cancer	0.000139	0.0021	CcSEcCtD
Anagrelide—Anorexia—Etoposide—muscle cancer	0.000138	0.00209	CcSEcCtD
Anagrelide—Diarrhoea—Dactinomycin—muscle cancer	0.000137	0.00207	CcSEcCtD
Anagrelide—Pneumonia—Methotrexate—muscle cancer	0.000137	0.00207	CcSEcCtD
Anagrelide—Depression—Methotrexate—muscle cancer	0.000136	0.00205	CcSEcCtD
Anagrelide—Hypotension—Etoposide—muscle cancer	0.000135	0.00204	CcSEcCtD
Anagrelide—Gastritis—Doxorubicin—muscle cancer	0.000135	0.00204	CcSEcCtD
Anagrelide—Renal failure—Methotrexate—muscle cancer	0.000134	0.00202	CcSEcCtD
Anagrelide—Conjunctivitis—Methotrexate—muscle cancer	0.000132	0.002	CcSEcCtD
Anagrelide—Dysphagia—Doxorubicin—muscle cancer	0.000132	0.002	CcSEcCtD
Anagrelide—Asthma—Doxorubicin—muscle cancer	0.000132	0.002	CcSEcCtD
Anagrelide—Influenza—Doxorubicin—muscle cancer	0.000132	0.002	CcSEcCtD
Anagrelide—Sweating—Methotrexate—muscle cancer	0.00013	0.00197	CcSEcCtD
Anagrelide—Paraesthesia—Etoposide—muscle cancer	0.00013	0.00196	CcSEcCtD
Anagrelide—Haematuria—Methotrexate—muscle cancer	0.00013	0.00196	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—muscle cancer	0.000129	0.00196	CcSEcCtD
Anagrelide—Dyspnoea—Etoposide—muscle cancer	0.000129	0.00195	CcSEcCtD
Anagrelide—Somnolence—Etoposide—muscle cancer	0.000129	0.00195	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—muscle cancer	0.000129	0.00194	CcSEcCtD
Anagrelide—Hepatobiliary disease—Methotrexate—muscle cancer	0.000129	0.00194	CcSEcCtD
Anagrelide—Epistaxis—Methotrexate—muscle cancer	0.000128	0.00194	CcSEcCtD
Anagrelide—Asthenia—Vincristine—muscle cancer	0.000128	0.00194	CcSEcCtD
Anagrelide—Vomiting—Dactinomycin—muscle cancer	0.000127	0.00192	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—muscle cancer	0.000127	0.00192	CcSEcCtD
Anagrelide—Rash—Dactinomycin—muscle cancer	0.000126	0.00191	CcSEcCtD
Anagrelide—Decreased appetite—Etoposide—muscle cancer	0.000126	0.0019	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—muscle cancer	0.000125	0.0019	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Etoposide—muscle cancer	0.000125	0.00189	CcSEcCtD
Anagrelide—Fatigue—Etoposide—muscle cancer	0.000125	0.00189	CcSEcCtD
Anagrelide—Constipation—Etoposide—muscle cancer	0.000124	0.00187	CcSEcCtD
Anagrelide—Pain—Etoposide—muscle cancer	0.000124	0.00187	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—muscle cancer	0.000123	0.00187	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—muscle cancer	0.000123	0.00185	CcSEcCtD
Anagrelide—Diarrhoea—Vincristine—muscle cancer	0.000122	0.00185	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—muscle cancer	0.000122	0.00184	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—muscle cancer	0.000122	0.00184	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—muscle cancer	0.000122	0.00184	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—muscle cancer	0.000121	0.00183	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—muscle cancer	0.000121	0.00182	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000121	0.00182	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—muscle cancer	0.00012	0.00182	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—muscle cancer	0.00012	0.00181	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—muscle cancer	0.000119	0.00181	CcSEcCtD
Anagrelide—Feeling abnormal—Etoposide—muscle cancer	0.000119	0.0018	CcSEcCtD
Anagrelide—Nausea—Dactinomycin—muscle cancer	0.000119	0.0018	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—muscle cancer	0.000118	0.00179	CcSEcCtD
Anagrelide—Gastrointestinal pain—Etoposide—muscle cancer	0.000118	0.00179	CcSEcCtD
Anagrelide—Dizziness—Vincristine—muscle cancer	0.000118	0.00179	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—muscle cancer	0.000118	0.00178	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—muscle cancer	0.000116	0.00175	CcSEcCtD
Anagrelide—Urticaria—Etoposide—muscle cancer	0.000115	0.00174	CcSEcCtD
Anagrelide—Abdominal pain—Etoposide—muscle cancer	0.000114	0.00173	CcSEcCtD
Anagrelide—Body temperature increased—Etoposide—muscle cancer	0.000114	0.00173	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—muscle cancer	0.000114	0.00173	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—muscle cancer	0.000114	0.00173	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—muscle cancer	0.000114	0.00172	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—muscle cancer	0.000114	0.00172	CcSEcCtD
Anagrelide—Vomiting—Vincristine—muscle cancer	0.000114	0.00172	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—muscle cancer	0.000113	0.00171	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—muscle cancer	0.000113	0.00171	CcSEcCtD
Anagrelide—Rash—Vincristine—muscle cancer	0.000113	0.0017	CcSEcCtD
Anagrelide—Dermatitis—Vincristine—muscle cancer	0.000113	0.0017	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—muscle cancer	0.000112	0.0017	CcSEcCtD
Anagrelide—Headache—Vincristine—muscle cancer	0.000112	0.00169	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000111	0.00168	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—muscle cancer	0.000111	0.00168	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—muscle cancer	0.00011	0.00167	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—muscle cancer	0.00011	0.00166	CcSEcCtD
Anagrelide—Chills—Methotrexate—muscle cancer	0.00011	0.00166	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—muscle cancer	0.000108	0.00163	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—muscle cancer	0.000106	0.00161	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—muscle cancer	0.000106	0.00161	CcSEcCtD
Anagrelide—Nausea—Vincristine—muscle cancer	0.000106	0.0016	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—muscle cancer	0.000106	0.0016	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—muscle cancer	0.000106	0.0016	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—muscle cancer	0.000106	0.0016	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—muscle cancer	0.000105	0.00159	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—muscle cancer	0.000105	0.00159	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—muscle cancer	0.000104	0.00158	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—muscle cancer	0.000104	0.00157	CcSEcCtD
Anagrelide—Asthenia—Etoposide—muscle cancer	0.000104	0.00157	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—muscle cancer	0.000104	0.00157	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—muscle cancer	0.000104	0.00157	CcSEcCtD
Anagrelide—Back pain—Methotrexate—muscle cancer	0.000103	0.00155	CcSEcCtD
Anagrelide—Pruritus—Etoposide—muscle cancer	0.000102	0.00155	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—muscle cancer	0.000102	0.00154	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—muscle cancer	0.0001	0.00151	CcSEcCtD
Anagrelide—Diarrhoea—Etoposide—muscle cancer	9.9e-05	0.0015	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—muscle cancer	9.88e-05	0.00149	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—muscle cancer	9.86e-05	0.00149	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—muscle cancer	9.85e-05	0.00149	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—muscle cancer	9.82e-05	0.00148	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—muscle cancer	9.81e-05	0.00148	CcSEcCtD
Anagrelide—Malaise—Methotrexate—muscle cancer	9.58e-05	0.00145	CcSEcCtD
Anagrelide—Dizziness—Etoposide—muscle cancer	9.57e-05	0.00145	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—muscle cancer	9.52e-05	0.00144	CcSEcCtD
Anagrelide—Chills—Doxorubicin—muscle cancer	9.48e-05	0.00143	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—muscle cancer	9.44e-05	0.00143	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—muscle cancer	9.34e-05	0.00141	CcSEcCtD
Anagrelide—Cough—Methotrexate—muscle cancer	9.27e-05	0.0014	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—muscle cancer	9.2e-05	0.00139	CcSEcCtD
Anagrelide—Vomiting—Etoposide—muscle cancer	9.2e-05	0.00139	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—muscle cancer	9.2e-05	0.00139	CcSEcCtD
Anagrelide—Rash—Etoposide—muscle cancer	9.13e-05	0.00138	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—muscle cancer	9.12e-05	0.00138	CcSEcCtD
Anagrelide—Headache—Etoposide—muscle cancer	9.07e-05	0.00137	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—muscle cancer	9.06e-05	0.00137	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—muscle cancer	9.04e-05	0.00137	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—muscle cancer	9.04e-05	0.00137	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—muscle cancer	9.04e-05	0.00137	CcSEcCtD
Anagrelide—Tension—Doxorubicin—muscle cancer	9.03e-05	0.00136	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.98e-05	0.00136	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—muscle cancer	8.94e-05	0.00135	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—muscle cancer	8.93e-05	0.00135	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—muscle cancer	8.9e-05	0.00135	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—muscle cancer	8.84e-05	0.00134	CcSEcCtD
Anagrelide—Confusional state—Methotrexate—muscle cancer	8.74e-05	0.00132	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—muscle cancer	8.67e-05	0.00131	CcSEcCtD
Anagrelide—Infection—Methotrexate—muscle cancer	8.61e-05	0.0013	CcSEcCtD
Anagrelide—Nausea—Etoposide—muscle cancer	8.6e-05	0.0013	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—muscle cancer	8.54e-05	0.00129	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—muscle cancer	8.5e-05	0.00129	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—muscle cancer	8.5e-05	0.00129	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—muscle cancer	8.49e-05	0.00128	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—muscle cancer	8.42e-05	0.00127	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—muscle cancer	8.38e-05	0.00127	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—muscle cancer	8.3e-05	0.00125	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—muscle cancer	8.26e-05	0.00125	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—muscle cancer	8.25e-05	0.00125	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—muscle cancer	8.13e-05	0.00123	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—muscle cancer	8.1e-05	0.00122	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—muscle cancer	8.09e-05	0.00122	CcSEcCtD
Anagrelide—Cough—Doxorubicin—muscle cancer	8.03e-05	0.00121	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—muscle cancer	7.97e-05	0.0012	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—muscle cancer	7.94e-05	0.0012	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—muscle cancer	7.9e-05	0.00119	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—muscle cancer	7.84e-05	0.00119	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—muscle cancer	7.83e-05	0.00118	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—muscle cancer	7.83e-05	0.00118	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—muscle cancer	7.83e-05	0.00118	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—muscle cancer	7.79e-05	0.00118	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.78e-05	0.00118	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—muscle cancer	7.74e-05	0.00117	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—muscle cancer	7.73e-05	0.00117	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—muscle cancer	7.71e-05	0.00117	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—muscle cancer	7.66e-05	0.00116	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—muscle cancer	7.63e-05	0.00115	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—muscle cancer	7.57e-05	0.00114	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—muscle cancer	7.54e-05	0.00114	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—muscle cancer	7.51e-05	0.00113	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—muscle cancer	7.49e-05	0.00113	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—muscle cancer	7.48e-05	0.00113	CcSEcCtD
Anagrelide—Infection—Doxorubicin—muscle cancer	7.46e-05	0.00113	CcSEcCtD
Anagrelide—Pain—Methotrexate—muscle cancer	7.41e-05	0.00112	CcSEcCtD
Anagrelide—Shock—Doxorubicin—muscle cancer	7.39e-05	0.00112	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—muscle cancer	7.36e-05	0.00111	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—muscle cancer	7.35e-05	0.00111	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—muscle cancer	7.33e-05	0.00111	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—muscle cancer	7.29e-05	0.0011	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—muscle cancer	7.26e-05	0.0011	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—muscle cancer	7.16e-05	0.00108	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—muscle cancer	7.14e-05	0.00108	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—muscle cancer	7.09e-05	0.00107	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—muscle cancer	7.02e-05	0.00106	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—muscle cancer	6.89e-05	0.00104	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—muscle cancer	6.85e-05	0.00104	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—muscle cancer	6.85e-05	0.00104	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.84e-05	0.00103	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—muscle cancer	6.79e-05	0.00103	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—muscle cancer	6.74e-05	0.00102	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—muscle cancer	6.69e-05	0.00101	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—muscle cancer	6.67e-05	0.00101	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—muscle cancer	6.61e-05	0.000999	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—muscle cancer	6.53e-05	0.000987	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.48e-05	0.00098	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—muscle cancer	6.47e-05	0.000979	CcSEcCtD
Anagrelide—Pain—Doxorubicin—muscle cancer	6.42e-05	0.000971	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—muscle cancer	6.42e-05	0.000971	CcSEcCtD
Anagrelide—Asthenia—Methotrexate—muscle cancer	6.22e-05	0.00094	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—muscle cancer	6.19e-05	0.000935	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—muscle cancer	6.14e-05	0.000928	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—muscle cancer	6.13e-05	0.000927	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—muscle cancer	5.96e-05	0.000902	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—muscle cancer	5.94e-05	0.000897	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—muscle cancer	5.94e-05	0.000897	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—muscle cancer	5.93e-05	0.000897	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—muscle cancer	5.73e-05	0.000867	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—muscle cancer	5.51e-05	0.000833	CcSEcCtD
Anagrelide—Rash—Methotrexate—muscle cancer	5.47e-05	0.000826	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—muscle cancer	5.46e-05	0.000826	CcSEcCtD
Anagrelide—Headache—Methotrexate—muscle cancer	5.43e-05	0.000821	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—muscle cancer	5.39e-05	0.000814	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—muscle cancer	5.31e-05	0.000803	CcSEcCtD
Anagrelide—Nausea—Methotrexate—muscle cancer	5.15e-05	0.000779	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—muscle cancer	5.14e-05	0.000777	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—muscle cancer	4.96e-05	0.000751	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—muscle cancer	4.77e-05	0.000722	CcSEcCtD
Anagrelide—Rash—Doxorubicin—muscle cancer	4.73e-05	0.000716	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—muscle cancer	4.73e-05	0.000715	CcSEcCtD
Anagrelide—Headache—Doxorubicin—muscle cancer	4.7e-05	0.000711	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—muscle cancer	4.46e-05	0.000674	CcSEcCtD
